This confidential document presents the sale of a fast-growing, multi-brand e-commerce portfolio specializing in research-use-only peptides. The business, having generated $21.3 million in the last twelve months, operates a 100% online model across several company-owned storefronts, focused mainly on five product categories. The standout brand, aligned with GLP-1/GLP-2 classes, is the primary revenue driver. The business boasts strong economics with an 88% gross margin and a 3% ad spend, supported by a 154,000-strong customer base where the repeat rate is 41%. To date, growth has been mainly organic with numerous opportunities for further expansion, including paid acquisition and international outreach. The founder seeks a complete sale on a debt-free, cash-free basis, offering flexibility in the transaction structure such as cash at closing, equity options, and performance-based earnouts. The business is well-suited for private equity or strategic acquisition thanks to its scalable platform. However, despite its rapid growth, the business is relatively new and has not been tested through an entire annual cycle, presenting potential risks related to regulatory factors and financial sustainability. For acquisition inquiries, interested parties must go through the designated advisor, with strict prohibitions against direct seller contact. Serious buyers should conduct diligent examinations into the regulatory, financial, and legal aspects given the high-risk nature of the product category.